Psychiatry

News

VistaGen's horizons may shrink after clinical trial setback

Shares in VistaGen Therapeutics have plummeted after the company reported that its lead pherine nasal spray candidate failed the first of two phase 3 trials in social anxiety disorder (SAD)

News

AbbVie adds to Vraylar data as FDA considers depression use

AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression, as it waits for a decision by the FDA on the new indicatio

News

Teva's long-acting schizophrenia drug rejected by FDA

Teva's long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company's long-acting formulation of schizophrenia drug risperidone

News

Fake Dictionary, Dictionary definition of the word Schizophrenia.

BioXcel gets first approval for agitation drug Igalmi

BioXcel Therapeutics has claimed its first product approval, getting a green light from the FDA for Igalmi as a treatment for agitation in people with schizophrenia or bipolar disorder.

News

AbbVie files Vraylar as add-on therapy for depression in US

AbbVie has filed with the FDA to extend the uses of its bipolar disorder therapy Vraylar to include adjunctive therapy for major depressive disorder, part of a plan to build sales of the dr

News

Sage, Biogen's zuranolone looks approvable, but will it sell...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response.

VistaGen's horizons may shrink after clinical trial setback

AbbVie adds to Vraylar data as FDA considers depression use

Teva's long-acting schizophrenia drug rejected by FDA

BioXcel gets first approval for agitation drug Igalmi

AbbVie files Vraylar as add-on therapy for depression in US

Sage, Biogen's zuranolone looks approvable, but will it sell...

As Ebola deaths climb, search begins for vaccine

Discover a new era of healthcare panel engagement: Grounded ...

Psychiatry

Editor's Picks